A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

115

Participants

Timeline

Start Date

November 27, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Solid Tumor

Interventions

DRUG

Test Product HYP-6589

HYP-6589 should be administered orally at the recommended dosage

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sichuan Huiyu Pharmaceutical Co., Ltd

INDUSTRY